“Neurimmune develops novel treatments for human diseases with high unmet medical needs. Our pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages, including molecules that are developed in collaboration with leading pharmaceutical companies”, said Roger Nitsch, President & CEO of Neurimmune. “Following our recent raise of $150 million, we are pleased that Dr. Buller joins our company to further drive our growth strategy. Dr. Buller has an impressive track record in business development and licensing transactions. He will play a key role in realizing opportunities that will allow us to bring novel therapeutics to patients.”

Prior to joining Neurimmune, Dr. Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. Dr. Buller holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.